Lexaria Bioscience Corp (LEXXW) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Lexaria Bioscience Corp (LEXXW) has a cash flow conversion efficiency ratio of -0.218x as of November 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-984.10K) by net assets ($4.52 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Lexaria Bioscience Corp - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Lexaria Bioscience Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Lexaria Bioscience Corp total liabilities for a breakdown of total debt and financial obligations.
Lexaria Bioscience Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lexaria Bioscience Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Clene Inc
NASDAQ:CLNNW
|
0.322x |
|
Hall of Fame Village LLC
NASDAQ:HOFVW
|
-0.053x |
|
Ordinary Fully Paid Deferred Settlement
AU:1TTDB
|
-0.108x |
|
Arko Corp
NASDAQ:ARKOW
|
0.132x |
|
Aquis Exchange PLC
LSE:AQX
|
0.057x |
|
BriaCell Therapeutics Corp
NASDAQ:BCTXW
|
-0.270x |
|
Ucommune International Ltd
NASDAQ:UKOMW
|
-0.017x |
|
immatics biotechnologies GmbH
NASDAQ:IMTXW
|
-0.064x |
Annual Cash Flow Conversion Efficiency for Lexaria Bioscience Corp (2005–2025)
The table below shows the annual cash flow conversion efficiency of Lexaria Bioscience Corp from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see Lexaria Bioscience Corp (LEXXW) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-08-31 | $2.60 Million | $-10.45 Million | -4.015x | -520.13% |
| 2024-08-31 | $7.66 Million | $-4.96 Million | -0.647x | +70.49% |
| 2023-08-31 | $2.68 Million | $-5.88 Million | -2.194x | -243.26% |
| 2022-08-31 | $7.63 Million | $-4.88 Million | -0.639x | -109.32% |
| 2021-08-31 | $13.06 Million | $-3.99 Million | -0.305x | +71.05% |
| 2020-08-31 | $2.48 Million | $-2.62 Million | -1.055x | +12.57% |
| 2019-08-31 | $2.49 Million | $-3.01 Million | -1.207x | -14.45% |
| 2018-08-31 | $2.39 Million | $-2.52 Million | -1.054x | -88.77% |
| 2017-08-31 | $2.77 Million | $-1.55 Million | -0.559x | +92.58% |
| 2016-08-31 | $87.76K | $-660.86K | -7.531x | -229.41% |
| 2015-08-31 | $656.60K | $-1.50 Million | -2.286x | -1594.78% |
| 2014-08-31 | $2.10 Million | $321.00K | 0.153x | 0.00% |
| 2013-08-31 | $2.10 Million | $321.00K | 0.153x | +6.02% |
| 2012-08-31 | $2.23 Million | $321.00K | 0.144x | +182.41% |
| 2011-08-31 | $2.66 Million | $135.94K | 0.051x | +11.09% |
| 2010-08-31 | $2.39 Million | $109.84K | 0.046x | +130.70% |
| 2009-08-31 | $2.21 Million | $-330.34K | -0.150x | -913.10% |
| 2008-08-31 | $2.46 Million | $-36.40K | -0.015x | -272.88% |
| 2007-08-31 | $3.39 Million | $29.04K | 0.009x | +102.76% |
| 2006-08-31 | $704.55K | $-218.56K | -0.310x | -120.33% |
| 2005-08-31 | $1.09 Million | $-153.38K | -0.141x | -- |
About Lexaria Bioscience Corp
Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall … Read more